Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This study is carried out to see how Caucasian patients with lung cancer which has EGFR
mutation will respond to gefitinib (IRESSA™) as a first line treatment. Safety data will also
be collected and analysed to confirm that treatment with gefitinib is safe and well
tolerated.